down arrow

GT Biopharma, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US36254L3087
USD
7.10
-0.08 (-1.11%)

Sep 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Biofrontera, Inc.
RenovoRx, Inc.
Aytu Biopharma, Inc.
Cingulate, Inc.
VYNE Therapeutics, Inc.
GT Biopharma, Inc.
Pasithea Therapeutics Corp.
Moleculin Biotech, Inc.
Eterna Therapeutics, Inc.
Iterum Therapeutics Plc
RVL Pharmaceuticals Plc

Why is GT Biopharma, Inc. ?

Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report

Verdict Report

Icon
No Data Found

Is GT Biopharma, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
GT Biopharma, Inc.
-65.57%
0.07
2118.03%
S&P 500
15.76%
1.20
13.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-30.45%
EBIT to Interest (avg)
-15.60
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.46
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.86%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.23
EV to EBIT
-0.48
EV to EBITDA
-0.48
EV to Capital Employed
-5.36
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1205.15%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
RAW MATERIAL COST(Y)

Fallen by 0% (YoY

PRE-TAX PROFIT(Q)

At USD -4.52 MM has Grown at 84.97%

NET PROFIT(Q)

At USD -4.52 MM has Grown at 84.97%

-6What is not working for the Company
INTEREST(9M)

At USD 0.25 MM has Grown at inf%

OPERATING CASH FLOW(Y)

Lowest at USD -14.43 MM

Here's what is working for GT Biopharma, Inc.

Pre-Tax Profit
At USD -4.52 MM has Grown at 84.97%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
At USD -4.52 MM has Grown at 84.97%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for GT Biopharma, Inc.

Interest
At USD 0.25 MM has Grown at inf%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Cash Flow
Lowest at USD -14.43 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Footer loading